NovelStem International Corp. reported a significant turnaround in its financial performance for the fiscal year ending December 31, 2025, achieving a net income of approximately $2.38 million compared to a net loss of $3.23 million in the previous year. The company’s current assets decreased to about $16,000 from $32,000, while current liabilities also fell sharply from $5.3 million to approximately $2.16 million. This improvement in net income was largely attributed to a gain of $1.17 million from the disposal of its investment in NetCo and relief of indebtedness income of approximately $1.7 million related to the settlement of a litigation funding agreement.
The company underwent significant operational changes during the fiscal year, including the liquidation of its former subsidiary, NewStem, which ceased operations in October 2024. As a result of this liquidation, NovelStem retained a financial interest of up to $3.75 million in any future licensing of the technology previously held by NewStem. The company also sold its 50% interest in NetCo for $1.3 million, which was used to settle related litigation liabilities. These strategic decisions reflect a shift in focus towards monetizing the remaining assets and rights associated with the NewStem technology.
In terms of operational metrics, NovelStem reported no revenue from its previous investments in NewStem during the fiscal years 2024 and 2025, and minimal distributions from NetCo. The company has not paid dividends since its name change in 2018 and does not anticipate doing so in the foreseeable future. As of March 25, 2026, NovelStem had approximately 49.3 million shares outstanding, held by around 80 record holders, with its stock trading on the OTC Pink Market.
Looking ahead, NovelStem's management emphasized the need for additional funding to support ongoing operations and the potential monetization of the license held by Yissum, the technology transfer company of Hebrew University. The company’s future success is contingent upon the ability to commercialize this license effectively. However, management acknowledged the inherent risks and uncertainties associated with their business model, including the challenges of competition and the rapid pace of technological change in the biotech sector.
Overall, NovelStem's financial results and strategic developments indicate a transitional phase as the company seeks to stabilize its operations and leverage its remaining assets for future growth. The management's focus on improving internal controls and financial reporting will be critical as they navigate the complexities of the biotech landscape and work towards achieving profitability.
About NovelStem International Corp.
NovelStem International Corp. is a holding company focused on biotech investments, primarily owning interests in NewStem Ltd., an Israeli biotech developing stem cell-based diagnostics and therapeutics, and a joint venture in entertainment properties. The company’s core activities involve managing biotech assets, licensing technology, and pursuing innovative medical research. It relies on investments and strategic partnerships, with a focus on advancing regenerative medicine and cancer diagnostics.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.